http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210154709-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2276405ae0e23cfcd15651de21c8565 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2021-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a630b8332e8889e18bed8cfa5335fd7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2f9127a1a235dbdb298eb6aabc0f142 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c29f5f146cc02061466b498444bf69c |
| publicationDate | 2021-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210154709-A |
| titleOfInvention | A pharmaceutical composition for the treatment of covid-19 respiratory syndrome |
| abstract | The present invention relates to a pharmaceutical composition for the treatment of human covid-19 respiratory syndrome comprising napamostat or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also relates to a useful dosage regimen when nafamostat or a pharmaceutically acceptable salt thereof is administered to a human for the purpose of treating Covid-19 respiratory syndrome. Furthermore, the present invention relates to a pharmaceutical composition comprising nafamostat or a pharmaceutical salt thereof as an active ingredient for treating a patient belonging to a particularly high-risk group among patients suffering from Covid-19 respiratory syndrome, and an early warning of 7 points or more. In Covid-19 Respiratory Syndrome patients with National Early Warning Score (NEWS), Covid-19 Respiratory Syndrome patients 65 years of age or older, or Covid-19 Respiratory Syndrome patients with oxygen saturation less than 90%, Covid-19 It relates to a pharmaceutical composition for ameliorating or recovering respiratory syndrome. |
| priorityDate | 2020-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.